‘CIIE Baby’ Paliperidone Palmitate Extended-Release Injection (Sustenna) Transitions from Exhibition to Market, Gaining Clinical Endorsement

At the 7th CIIE, Johnson & Johnson's long-acting injectable drug Sustenna, administered once every six months, was launched in China for adult schizophrenia patients who have received adequate treatment with paliperidone palmitate injection (3M) for at least three months.

It is reported that this is the third time for Sandostatin to appear at the CIIE. In June this year, Sandostatin was approved by the National Medical Products Administration of China, and in October, Sandostatin officially entered multiple hospitals across China, successfully benefiting patients.

Reporter: Di Chun

Produced by the Audio and Video Department of Xinhua News Agency